First Quadrant L P CA lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6,526.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 129,815 shares of the pharmaceutical company’s stock after acquiring an additional 127,856 shares during the period. First Quadrant L P CA owned approximately 0.05% of Vertex Pharmaceuticals worth $19,737,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also bought and sold shares of the company. Northwestern Mutual Wealth Management Co. grew its stake in shares of Vertex Pharmaceuticals by 15.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock valued at $127,000 after buying an additional 132 shares during the period. FNY Partners Fund LP boosted its stake in Vertex Pharmaceuticals by 900.0% during the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock valued at $128,000 after purchasing an additional 900 shares during the last quarter. Dupont Capital Management Corp acquired a new position in Vertex Pharmaceuticals during the 2nd quarter valued at about $186,000. State of Alaska Department of Revenue acquired a new position in Vertex Pharmaceuticals during the 2nd quarter valued at about $197,000. Finally, Tocqueville Asset Management L.P. acquired a new position in Vertex Pharmaceuticals during the 2nd quarter valued at about $203,000. 92.79% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Sangeeta N. Bhatia sold 7,073 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $143.05, for a total value of $1,011,792.65. Following the sale, the director now owns 11,026 shares in the company, valued at $1,577,269.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Ian F. Smith sold 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $145.06, for a total transaction of $10,879,500.00. Following the completion of the sale, the chief operating officer now owns 114,188 shares in the company, valued at approximately $16,564,111.28. The disclosure for this sale can be found here. Insiders have sold 220,094 shares of company stock valued at $32,074,719 in the last ninety days. Insiders own 1.80% of the company’s stock.
A number of equities analysts have issued reports on the company. Raymond James Financial, Inc. upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $181.00 price target for the company in a research note on Wednesday, July 19th. J P Morgan Chase & Co set a $175.00 price target on Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, July 19th. Oppenheimer Holdings, Inc. boosted their target price on Vertex Pharmaceuticals from $150.00 to $175.00 and gave the stock an “outperform” rating in a research note on Thursday, July 27th. BMO Capital Markets restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, September 27th. Finally, Robert W. Baird restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-three have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $173.15.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $147.82 on Wednesday. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $167.85. The stock has a market cap of $37,616.77, a PE ratio of 247.90, a P/E/G ratio of 3.78 and a beta of 1.63. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The business had revenue of $578.20 million during the quarter, compared to the consensus estimate of $522.07 million. During the same quarter last year, the firm earned $0.16 earnings per share. The business’s revenue for the quarter was up 39.7% on a year-over-year basis. analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.72 EPS for the current year.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.